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Abstract
Background: A limited number of publications have assessed the prevalence of hypertension (HTN) in polycystic
ovary syndrome (PCOS) patients with inconclusive results. Since in general populations the occurrence of
hypertension is related to age per se, we investigated the prevalence (P) / relative risk (RR) of HTN in pooled
patients with PCOS, vs control population among reproductive age women with PCOS, compared to menopause/
aging patients.
Methods: PubMed, Scopus, ScienceDirect, web of science, and Google scholar were systematically searched for
retrieving observational studies published from inception to April 2019 investigating the HTN in patients with PCOS.
The primary outcome of interest was pooled P and RR of HTN in reproductive and menopausal/aging women with
PCOS compared to control population.
Results: The pooled prevalence of HTN in reproductive and menopausal/aging women with PCOS was higher than
in the control population [(Pooled P: 0.15, 95% CI: 0.12–0.18 vs. Pooled P: 0.09, 95% CI: 0.08–0.10) and (Pooled P:
0.49, 95% CI: 0.28–0.70 vs. Pooled P: 0.40, 95% CI: 0.22–0.57), respectively]. Compared to the control population,
pooled relative risk (RR) of HTN patients was increased only in reproductive age PCOS (1.70-fold, 95% CI: 1.43–2.07)
but not in menopausal/aging patients who had PCOS during their reproductive years. The same results were
obtained for subgroups of population-based studies. Meta-regression analysis of population-based studies showed
that the RR of HTN in reproductive age PCOS patients was 1.76-fold than menopausal/aging PCOS patients (P =
0.262).
Conclusion: This meta-analysis confirms a greater risk of HTN in PCOS patients but demonstrates that this risk is
increased only in reproductive age women with PCOS, indicating that after menopause, having a history of PCOS
may not be as an important predisposing factor for developing HTN.
Keywords: Meta-analysis, Hypertension, Polycystic ovary syndrome, Relative risk
Background
Polycystic ovary syndrome (PCOS), a prevalent endocrine
and metabolic condition in reproductive age women [1], is
a heterogeneous disorder that is associated to increased
cardiovascular risk. Previous studies have demonstrated
that almost all cardiovascular (CV) risk factors including
obesity, insulin resistance, diabetes mellitus, atherogenic
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dyslipidemia, metabolic syndrome, C-reactive protein are
elevated in patients with PCOS [2–6]; these risk factors
are present even in young PCOS patients and predispose
to development of early atherosclerosis, cardiovascular
morbidity and mortality [5, 7, 8].
Androgen excess in patients PCOS is clearly associated
with an increased prevalence of cardio-metabolic distur-
bances [9]. Evidence demonstrated that an increased preva-
lence of subclinical atherosclerosis, endothelial dysfunction,
increased carotid intima media thickness and coronary ar-
tery calcification in PCOS patients [6]. Shroff et al. showed
a 5-fold higher prevalence of subclinical coronary athero-
sclerosis in young obese women with PCOS, compared to
general population [10]. The prevalence of coronary artery
calcification is 4-fold higher than control population (39.0%
vs. 9.9%) [11]. It is well documented that PCOS in young
women is associated with endothelial dysfunction [4, 12].
Previous studies showed an atherogenic lipid profile and in-
creased plasminogen activator type 1 (PAI-I) production in
PCOS patients, which these risk factors are important for
developing cardiovascular disease [13, 14].
While hypertension (HTN) represents one of the main
cardiovascular risk factors in general populations, only a
few studies have investigated HTN in women with PCOS
and these have with contrasting results [15–19]. On the
other hand, it is not yet known whether increased risk of
HTN modifies by aging [19].
To get more information on the prevalence and the evo-
lution of HTN in women with PCOS, we performed a
meta-analysis of available data assessing the prevalence and
risk of HTN not only in all women with PCOS but also in
these patients divided according to their age (reproductive
and postmenopausal). In both approaches, population
based and non-population-based studies were analyzed
separately.
Materials and methods
This systematic review and meta-analysis was designed
according to the guidelines for the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) [20] and the Cochrane Handbook for System-
atic Review of Interventions [21] to investigate the
pooled prevalence (P) / RR of HTN:
1- In reproductive and menopausal/aging PCOS
groups, compared to control population.
2- In reproductive and menopausal/aging PCOS
groups compared to control population in
population-based studies.
3- Between reproductive age PCOS women compared
to menopausal/aging group.
4- Between reproductive age PCOS women compared
to those in menopausal/aging group in population-
based studies.
Search strategy
In this meta-analysis, PubMed, Scopus, ScienceDirect,
web of science, and Google scholar were searched for re-
trieving observational studies published from inception to
April 2019 investigating the HTN in patients with PCOS.
Before initiation of the study, we conducted the search
strategy with the assistance of a professional healthcare li-
brarian. All reviewers performed searches separately. At
first, search in the PubMed was performed based on con-
trol vocabularies (MESH) using the following formula:
(“Polycystic ovary syndrome” OR “PCOS”) AND (“cardio-
vascular” OR “cardio-metabolic” OR “metabolic” OR
“hypertension” OR “hypertensive” OR “blood pressure”).
We also searched PubMed and other databases using
free-text terms. Search criteria were humans, and English
language. Search strategy was almost similar for all data-
bases. The searches were done based on the ‘all fields’ in
the PubMed and ‘titles, abstracts and keywords’ in other da-
tabases. A ‘pearl growing’ strategy was employed, whereby,
after obtaining the full text articles, the reference lists of all
included studies were reviewed for additional publications
that could be used in this review.
Eligibility criteria
Analytic observational studies of all types including cross-
sectional, case-control, and cohort designs that assessed
hypertension in women with PCOS were eligible to be in-
cluded in the meta-analysis. In addition, studies needed to
report a risk ratio (odds ratio [OR], relative risk [RR], or
hazard ratio) or should have provided sufficient informa-
tion to allow calculation of a relevant effect estimate. We
included studies using National Institutes of Health (NIH)
[22], Rotterdam [23], Androgen Excess Society (AES) [24],
laparoscopic [25] and International Classification of Dis-
eases (ICD) [26] as diagnostic criteria for PCOS.
Exclusion criteria included: (1) studies that did not dif-
ferentiate between women and men, (2) studies that did
not assess any cardiovascular events, (3) studies with un-
reliable and incomplete results, and (4) studies with un-
known or invalid PCOS diagnostic criteria.
Study selection
We included all relevant studies assessing hypertension in
women with PCOS. The results of the searches were
screened based on predefined eligibility criteria. All refer-
ences were entered to EndNote X7 software (Thomson
Reuters, New York, NY, USA). Initial selection was per-
formed based on their titles, followed by a second selection
performed by one reviewer (M.A), who deleted duplicates
and reviewed the abstracts of all remaining records. Any
disagreement in the selection of abstracts was resolved by
consensus or by two other reviewers (F.R.T and E.C). Full
text articles for review and data processing were obtained
for all selected abstracts.
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Data extraction
Two reviewers (M.A and S.B.G), in close consultation
with another reviewer (F.R.T), extracted data from full
text articles; they rechecked all precisely extracted data to
minimize errors. For each study, the following informa-
tion was extracted: Authors, year of publication, title,
study design (cross-sectional, case-control, cohort), char-
acteristics of study population, number of events, and the
unadjusted or adjusted risk ratios provided (OR, RR, or
hazard ratio) by each outcome. To prevent extraction er-
rors, all reviewers performed a quality control check be-
tween the final data used in the meta-analysis and the
original publications.
Quality assessment
All studies included for the meta-analysis were appraised for
the quality of their methodological and result presentation.
Two reviewers (M.A and S.B.G) assessed the quality of the
studies separately. They were blinded to study author,
institution, and journal name. Disagreement was resolved
and adjusted by other reviewers (F.R.T). All observational
studies including cross-sectional, case-control, and cohort
were appraised according to the Newcastle–Ottawa scale
[27]. In this respect, 3 domains were scored for selection
and comparability of study cohorts, and determination of
the outcome of interest. If a study obtained ≥70% of the
highest level of the Newcastle–Ottawa scale, it was consid-
ered to be of high quality, 40–70% as moderate, and 20 to
40% as low and < 20% as very low quality (Supplementary
File 1).
Risk of bias assessment
We assessed the risk of bias in each study included, using
the Cochrane Collaboration’s tools, which have been de-
signed for various methodological studies including cross-
sectional, case-control, and cohorts. Review authors’ judg-
ments were categorized as “low risk,” “high risk,” and “un-
clear risk” of bias (either low or high risk of bias) [28].
Fig. 1 PRISMA flow diagram of search strategy and study selection
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Outcome measures
The primary outcome of interest was hypertension, which
was defined as systolic blood pressure (SBP) ≥ 140mmHg
and diastolic blood pressure (DBP) ≥ 90mmHg or current
use of anti-hypertensive medicine [29].
Statistical analysis
We performed a meta-analysis to estimate the pooled P
/ RRs of HTN. Heterogeneity was evaluated using the I-
squared (I2) statistics; values above 50% were interpreted
as heterogeneity. Both random and fixed effect models
were used for heterogeneous and non-heterogeneous re-
sults, respectively. Publication bias was assessed using
the Begg’s test [30]; bias was found to be significant for
P-values < 0.05. The trim and fill method was not used
because of non-significant results [31].
Pooled P and pooled RR (Pooled RR) were used for
reporting results of the meta-analysis. The “Meta-prop”
method was applied for the pooled estimation of the preva-
lence of HTN [32]; pooled RR was also estimated by the
“Metan” method, using the normal distribution to estimate
confidence intervals. Mantel–Haenszel method was used to
estimate pooled data [33].
Subgroup analyses were performed to assess the pooled
P / RR of HTN, based on age groups (reproductive vs.
menopausal/aging) and study design (population- vs. non-
population-based studies). Forest plots were drawn for RR
of HTN in the mentioned subgroups as well.
Furthermore, the random effect meta-regression model
was fitted to estimate the association between age groups
and outcome of interest (here RR of HTN) in subgroups
of study design. Bubble plots were drawn to illustrate the
fitted models for each covariate.
We also adjust BMI and diabetes mellitus as a con-
founding variable to decrease the source of heterogen-
eity. Sensitivity analyses were performed to explore the
source of heterogeneity with detecting the influence of
any single study on the prevalence or relative risk of
outcomes. Statistical analysis was performed using




Figure 1 presents the search strategy and study selection. Of
5236 records retrieved through searching databases 30 stud-
ies including 17 population based [2, 3, 7, 19, 34–48] and 11
non-population based studies [4, 5, 10, 34, 49–56] were se-
lected for the final analyses. Twenty-four studies assessed a
population of reproductive age patients with PCOS [2, 3, 5,
7, 10, 34–38, 40, 41, 43–47, 49–51, 53–56], 4 studies- meno-
pausal/aging women [19, 39, 52, 57], and two studies- both
age groups of patients (reproductive and menopausal/aging
Table 2 Meta-analysis of studies included conducted on the prevalence of HTN
HTN Number of observations I2 aPublication bias Pooled Prevalence (95%CI)
All studies
Reproductive age 52 99 0.567 0.11 (0.10, 0.12)
Case 26 99 0.459 0.15 (0.12, 0.18)
Control 26 99 0.867 0.09 (0.08, 0.10)
Menopause/ aging 12 95 0.498 0.44 (0.32, 0.56)
Case 6 65 0.504 0.49 (0.28, 0.70)
Control 6 97 0.259 0.40 (0.22, 0.57)
Population based studies
Reproductive age 28 99 0.768 0.09 (0.08, 0.11)
Case 14 99 0.343 0.12 (0.08, 0.15)
Control 14 99 0.218 0.08 (0.06, 0.09)
Menopause/ aging 4 94 0.250 0.50 (0.33, 0.68)
Case 2 – 0.317 0.60 (0.52, 0.68)
Control 2 – 0.317 0.44 (0.40, 0.48)
Non-Population based studies
Reproductive age 24 93 0.768 0.16 (0.12, 0.19)
Case 12 94 0.987 0.20 (0.14, 0.26)
Control 12 94 0.800 0.12 (0.08, 0.16)
Menopause/ aging 8 93 0.328 0.41 (0.26, 0.55)
Case 4 97 0.250 0.47 (0.21, 0.73)
Control 4 95 0.243 0.35 (0.11, 0.59)
I2 I-squared
a assessed by Begg’s test
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women) [4, 48]. Table 1 shows characteristics of studies in-
cluded. Details of quality assessment are presented as sup-
plementary file 1.
Meta-analysis and meta-regression of outcomes
The review showed that the pooled prevalence of HTN
in reproductive and menopausal/aging women with
PCOS was higher than in the general population
[(Pooled P: 0.15, 95% CI: 0.12–0.18 vs. Pooled P: 0.09,
95% CI: 0.08–0.10) and (Pooled P: 0.49, 95% CI: 0.28–
0.70 vs. Pooled P: 0.40, 95% CI: 0.22–0.57), respectively].
The same results were obtained when only population-
based studies were included in the meta-analysis
[(Pooled P: 0.12, 95% CI: 0.08–0.15 vs. Pooled P: 0.08,
95% CI: 0.06–0.09) and (Pooled P: 0.60, 95% CI: 0.52–
0.68 vs. Pooled P: 0.44, 95% CI: 0.40–0.48), respectively]
(Table 2).
Figures 2, 3 and 4 illustrate the forest plots of pooled
RRs of HTN in patients with PCOS, compared to con-
trol population. The RR of HTN in patients with PCOS
was 1.60-fold (95% CI: 1.36–1.87) higher than in con-
trol population. Subgroup analysis based on the age
groups revealed that the pooled RR of HTN in repro-
ductive age PCOS patients was 1.70-fold (95% CI: 1.43–
Fig. 2 Forest plot of pooled relative risk of hypertension. Relative risk < 1 shows measures of in favor of PCOS (left side) and relative risk values >
1 are in favor of control population (right side)
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2.07) higher than in control populations of similar ages,
but that the RR of HTN in menopausal/aging patients
was not significantly different compared to the control
population (Table 3, Fig. 2). Subgroup analysis of
population-based studies revealed the same results; the
pooled RR of HTN in reproductive age PCOS patients
was 1.87-fold (95% CI: 1.51–2.33) higher than control
population, while no significant difference was observed
for menopausal/aging group (Table 3, Fig. 3). Figure 4
illustrates the forest plot of pooled RR of HTN for non-
population based studies.
Meta-regression analysis based on all studies, population-
based and non-population-based studies is presented in
Fig. 5. Meta-regression analysis of population-based studies
showed that the RR of HTN in reproductive age PCOS pa-
tients was 1.76-fold (95% CI: 0.65–5.30) higher than those
of HTN in menopausal/aging PCOS patients (P = 0.262).
After adjusting the model with BMI and diabetes mellitus
result did not significantly change (Table 4).
There were significant heterogeneities in prevalence
and RR of HTN among studies included in most sub-
groups of the study (Tables 2 and 3).
Publication bias, risk of bias and sensitivity analysis
Egger’s test did not show any significant publication bias
among studies included for HTN; therefore, trim and fill
correction were not required (Tables 2 and 3).
Most cross-sectional and case-control studies had a
low risk of bias in domains of assessment of exposure,
development of outcome of interest in cases and con-
trols, selection of cases, and selection of controls, and a
high risk of bias in control of the prognostic variable. In
the cohort studies, a low risk of bias selection of exposed
and non-exposed cohorts, assessment of exposure,
Fig. 3 Forest plot of pooled relative risk of hypertension for population based studies. Relative risk < 1 shows measures of in favor of PCOS (left
side) and relative risk values > 1 are in favor of control population (right side)
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presence of outcome of interest at start of study, out-
come assessment, and adequate follow up of cohorts
were observed; however, we found a high risk of bias in
control of prognostic variables and assessment of the
presence or absence of prognostic factors (Supplemen-
tary File 1).
Sensitivity analysis suggested that the pooled RR and
prevalence of hypertension were stable and excluding a
single study did not change the significance of the
pooled RR (Supplementary File 1). Since sensitivity ana-
lysis detected no significant heterogeneous study, the
study type had no effect on the prevalence of hyperten-
sion. We also excluded the Rotterdam criteria and re-
sun analyses; the results were analogues with the previ-
ous findings, indicating that the PCOS criteria had no
significant effect on our results (supplementary File 1).
Discussion
A large number of patients with PCOS, particularly
those with hyperandrogenic phenotypes, present with
several cardiometabolic risk factors that increase their
chance for developing vascular abnormalities and hyper-
tension [15, 59]. Androgen excess in PCOS may also dir-
ectly influence the vascular properties of arterial walls
and the expression of molecules involved in the athero-
genic process [60]. However, contrasting results on the
prevalence of hypertension in PCOS have been reported
by some studies suggesting increased prevalence [3, 7,
35, 36, 38, 40, 41, 43], whereas others find no significant
differences in general populations [2, 19, 39, 42, 44–47].
In this meta-analysis, we found that, prevalence of
hypertension is higher in PCOS patients compared to
control population. Limiting the included studies to
Fig. 4 Forest plot of pooled relative risk of hypertension for non-population based studies. Relative risk < 1 shows measures of in favor of PCOS
(left side) and relative risk values > 1 are in favor of control population (right side)
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Table 3 Meta-analysis of studies included conducted on the relative risk (RR) of HTN
HTN Number of study groups I2% aPublication bias Pooled RR (95%CI)
All studies
Reproductive 25 97 0.779 1.70 (1.43, 2.07)
Menopause/aging 6 85 0.497 1.26 (0.95, 1.67)
Total 21 97 0.586 1.60 (1.36, 1.87)
Population based studies
Reproductive 14 99 0.213 1.87 (1.51, 2.33)
Menopause/aging 2 – 0.317 1.06 (0.89, 1.25)
Total 16 99 0.186 1.73 (1.41, 2.13)
Non- Population based studies
Reproductive 11 47 0.675 1.41 (1.14, 1.71)
Menopause/aging 4 88 0.317 1.45 (0.91, 2.31)
Total 15 64 0.465 1.40 (1.16, 1.71)
I2 I-squared
a assessed by Begg’s test
Fig. 5 Bubble plot of association between relative risk of hypertension and age group (a total studies, b population-based studies, c non-
population based studies). The solid black line represents the weighted regression line based on variance-weighted least squares. The circles
indicate RRs in each study. The circle size is proportional to the precision of the RR. The vertical axis is on a log scale
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population-based studies also showed that hypertension
was more common in the PCOS than controls.
Because prevalence of HTN is increased in postmeno-
pausal and aging women, we have separately assessed re-
productive age PCOS patients and postmenopausal
women who had PCOS during their reproductive period;
results showed that, hypertension was more common
only reproductive age PCOS women (OR 1.94, p = 0.01);
this finding remained significant even after adjustment
for BMI and diabetes mellitus.
Nevertheless, the data available suggest that the increased
risk for HTN in PCOS patients ameliorates with aging [61],
becoming normal in postmenopausal women who had
PCOS during their reproductive age. Our current findings
are parallel and in some way anticipate the data we ob-
served in a recent meta-analysis that assesses the prevalence
of cardiovascular events in PCOS subjects; in that study,
cardiovascular events were also increased in young PCOS
patients but normalized when postmenopausal PCOS
women compared to control women of similar ages [62].
Because HTN is one of the main cardiovascular risks, it is
probable that normalization of the prevalence of HTN with
age plays a main role in the normalization of cardiovascular
events.
Mechanisms determining the reduction of the risk of
HTN by ageing are unclear, although the progressive de-
crease of androgens during adult reproductive ages may
play a main role; a progressive decrease of serum testoster-
one in both general populations and in PCOS women is ob-
served many years before the occurrence of menopause
[63]. A follow-up study showed that approximately 50% of
PCOS patients improve during late reproductive age be-
cause of ovarian and adrenal aging that leads to decreasing
androgen levels, which can result in a progressive decrease
in cardiovascular risk factors [64]. Other longitudinal stud-
ies demonstrated that some cardiovascular risk factors in
women with PCOS may be progressively decreased with
aging [45, 59] .
The main limitation of this meta-analysis is the small
number of studies assessing HTN in postmenopausal
PCOS women [4, 19, 39, 52]. In addition, some studies
did not report a crude relative risk or the exact number
of HTN cases, nor did have a risk of bias in the control
of confounders. Although the risk of bias in these studies
assessing postmenopausal women was low with no dif-
ferences in RR for HTN compared to young patients.
For this study, we used data of hypertension based on
the previous JNC7 criteria (SBP ≥140 mmHg or DBP
≥90mmHg) [56], moreover most studies did not report
details of the BP measurement methods and standard
conditions, which could affect the accuracy and validity
of results; hence, caution should be considered to inter-
pret findings. Finally, the possible influence of body
weight and obesity on reported results could not be
assessed because of the paucity of related data.
Conclusions
Increasing risk for hypertension in PCOS women com-
pared to controls is observed only in reproductive age
but not in menopausal women with history of PCOS
during reproductive period. After menopause, having a
history of PCOS may not be as an important risk factor
for developing HTN.
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All studies 0.86 (.47, 1.2), 0.80 (0.32, 1.8), 0.85 (0.38, 2.5),
P = 0.225 P = 0.221 P = 0.129
Population-based studies 1.76 (0.65–5.30), 1.25(.81–1.93), 1.65 (0.72–1.81),
P = 0.262 P = 0.125 P = 0.223
Non-population-based
studies
0.71(.38, 1.3), 0.65 (0.22, 1.9), 0.71 (0.12, 2.1),
P = 0.233 P = 0.325 P = 0.110
aProportion of relative risk for reproductive vs menopause aging
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healthy control of menopause aging group. Figure S9. The result of sen-
sitivity analysis for all age subgroups. Figure S10. The result of sensitivity
analysis for reproductive age subgroup. Figure S11. The result of sensi-
tivity analysis for menopause/aging subgroup. Figure S12. Forest plot of
pooled relative risk of HTN for all studies except those with Rotterdam
criteria. Figure S13. Forest plot of pooled relative risk of HTN for all
population based studies except those with Rotterdam criteria. Figure
S14. Forest plot of pooled relative risk of HTN for all non-population
based studies except those with Rotterdam criteria.
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